Esparham Ali, Sheikhbahaei Erfan, Anari Moghadam Hengameh, Khorgami Zhamak
Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran.
Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran.
Obes Surg. 2025 Aug 9. doi: 10.1007/s11695-025-08137-4.
This study aimed to systematically review existing evidence on the preoperative use of GLP-1 receptor agonists (GLP-1 RA) before metabolic and bariatric surgery (MBS). Web of Science, Embase, PubMed, and Scopus were searched systematically with relevant keywords for articles on the effect of preoperative GLP-1 RA use on MBS outcomes. Eleven observational studies evaluated the effects of preoperative GLP-1 RAs. GLP-1 RAs enhance preoperative weight loss with earlier optimization for MBS. Preoperative use of these agents were associated with increased postoperative nausea but showed no significant differences in the rate of major complications or readmissions. Benefits included improved diabetes outcomes, although findings on postoperative weight loss were inconsistent, and some studies reported higher surgical adhesion rates. More robust evidence is needed to guide the incorporation of GLP-1 RAs into preoperative pathways for MBS.
本研究旨在系统回顾代谢和减重手术（MBS）前使用胰高血糖素样肽-1受体激动剂（GLP-1 RA）的现有证据。我们使用相关关键词在科学网、Embase、PubMed和Scopus数据库中系统检索关于术前使用GLP-1 RA对MBS结局影响的文章。11项观察性研究评估了术前GLP-1 RA的作用。GLP-1 RA可促进术前体重减轻，并能更早地为MBS进行优化。术前使用这些药物与术后恶心增加有关，但在主要并发症发生率或再入院率方面无显著差异。其益处包括改善糖尿病结局，尽管术后体重减轻的结果并不一致，且一些研究报告手术粘连率更高。需要更有力的证据来指导将GLP-1 RA纳入MBS术前路径。
